COMP <GO>
KYMR vs UNH // FREE CASH FLOW YIELD
Kymera Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KYMR 5
— UNH 9
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
fcf-yield
-2.30%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.00% | 88.57% | -88.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 11.47% | -32.87 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -2.30% | 6.48% | -8.78 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 6.46% | -23.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | KYMR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.3 | 56.0 | +13.28 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 17.1x | +13.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $364.66B | -$354.46B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | UNH REV | KYMR GROSS % | UNH GROSS % | KYMR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $447.57B | 0.0% | 88.7% | -$234.3M | $16.07B |
| FY 2024 | $47.1M | $400.28B | 0.0% | 88.3% | -$207.3M | $20.70B |
| FY 2023 | $78.6M | $371.62B | 44.0% | 89.6% | -$106.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
UNH // BETA 0.33